The future of Johnson & Johnson's cancer blockbuster Zytiga is in doubt, after a US patent ruling has opened the door to generic competitors. Johnson & Johnson’s Q4 results were hit by a one-off ...
Erleada is a successor to J&J’s Zytiga (abiraterone), which has gone off patent in the US and succumbing to generic competition – sales of the blockbuster were down nearly 60% in Q2 in the US ...
Hosted on MSN3mon
Medicare Pays Wildly Different Prices for the Same DrugThe cost of prescription drugs in the U.S. isn’t like the tabs for other products. The price for a single medicine can range by thousands of dollars depending on the drug plan. It is a symptom ...
The CAPItello-281 study evaluated the combination of Truqap, J&J’s JNJ Zytiga (abiraterone) and androgen deprivation therapy (ADT) in patients with PTEN-deficient de novo metastatic hormone ...
It was designed as an alternative abiraterone acetate formulation with clear benefits over branded Zytiga tablets. TAVT-45 granules are rapidly reconstituted in water or juice and easily consumed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback